CN114288305B - Skin repair composition and preparation method thereof - Google Patents
Skin repair composition and preparation method thereof Download PDFInfo
- Publication number
- CN114288305B CN114288305B CN202111617732.1A CN202111617732A CN114288305B CN 114288305 B CN114288305 B CN 114288305B CN 202111617732 A CN202111617732 A CN 202111617732A CN 114288305 B CN114288305 B CN 114288305B
- Authority
- CN
- China
- Prior art keywords
- composition
- skin
- stirring
- ammonium salt
- phase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 94
- 230000008439 repair process Effects 0.000 title claims abstract description 28
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims abstract description 72
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 58
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims abstract description 38
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims abstract description 36
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims abstract description 36
- 235000005875 quercetin Nutrition 0.000 claims abstract description 36
- 229960001285 quercetin Drugs 0.000 claims abstract description 36
- 235000012000 cholesterol Nutrition 0.000 claims abstract description 29
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims abstract description 27
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims abstract description 27
- 229940106189 ceramide Drugs 0.000 claims abstract description 27
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims abstract description 27
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims abstract description 27
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 21
- 239000000194 fatty acid Substances 0.000 claims abstract description 21
- 229930195729 fatty acid Natural products 0.000 claims abstract description 21
- 150000004665 fatty acids Chemical class 0.000 claims abstract description 21
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims abstract description 19
- 239000001768 carboxy methyl cellulose Substances 0.000 claims abstract description 19
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims abstract description 19
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims abstract description 19
- 238000003756 stirring Methods 0.000 claims abstract description 19
- 238000002156 mixing Methods 0.000 claims abstract description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 18
- 239000002562 thickening agent Substances 0.000 claims abstract description 17
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 16
- 150000001412 amines Chemical class 0.000 claims abstract description 12
- 229940107161 cholesterol Drugs 0.000 claims abstract description 10
- 239000004519 grease Substances 0.000 claims abstract description 8
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 26
- 229920002125 Sokalan® Polymers 0.000 claims description 26
- 229960001631 carbomer Drugs 0.000 claims description 26
- 239000000230 xanthan gum Substances 0.000 claims description 25
- 229920001285 xanthan gum Polymers 0.000 claims description 25
- 229940082509 xanthan gum Drugs 0.000 claims description 25
- 235000010493 xanthan gum Nutrition 0.000 claims description 25
- 150000003863 ammonium salts Chemical class 0.000 claims description 23
- 230000003716 rejuvenation Effects 0.000 claims description 14
- 239000003921 oil Substances 0.000 claims description 10
- 229920001577 copolymer Polymers 0.000 claims description 9
- OMIGHNLMNHATMP-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate Chemical compound OCCOC(=O)C=C OMIGHNLMNHATMP-UHFFFAOYSA-N 0.000 claims description 8
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 6
- -1 amine salt Chemical class 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- WOWHHFRSBJGXCM-UHFFFAOYSA-M cetyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)C WOWHHFRSBJGXCM-UHFFFAOYSA-M 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 claims description 6
- FWFUWXVFYKCSQA-UHFFFAOYSA-M sodium;2-methyl-2-(prop-2-enoylamino)propane-1-sulfonate Chemical compound [Na+].[O-]S(=O)(=O)CC(C)(C)NC(=O)C=C FWFUWXVFYKCSQA-UHFFFAOYSA-M 0.000 claims description 5
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 4
- 150000003242 quaternary ammonium salts Chemical group 0.000 claims description 3
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 claims description 3
- MPNXSZJPSVBLHP-UHFFFAOYSA-N 2-chloro-n-phenylpyridine-3-carboxamide Chemical compound ClC1=NC=CC=C1C(=O)NC1=CC=CC=C1 MPNXSZJPSVBLHP-UHFFFAOYSA-N 0.000 claims description 2
- 229920000289 Polyquaternium Polymers 0.000 claims description 2
- VBIIFPGSPJYLRR-UHFFFAOYSA-M Stearyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)C VBIIFPGSPJYLRR-UHFFFAOYSA-M 0.000 claims description 2
- 125000005211 alkyl trimethyl ammonium group Chemical group 0.000 claims description 2
- 239000012467 final product Substances 0.000 claims description 2
- 235000021588 free fatty acids Nutrition 0.000 claims description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 claims description 2
- 229940032094 squalane Drugs 0.000 claims description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 1
- 230000029663 wound healing Effects 0.000 abstract description 26
- 230000001737 promoting effect Effects 0.000 abstract description 13
- 206010072170 Skin wound Diseases 0.000 abstract description 6
- 201000004624 Dermatitis Diseases 0.000 abstract description 4
- 241000700159 Rattus Species 0.000 description 22
- 206010052428 Wound Diseases 0.000 description 21
- 208000027418 Wounds and injury Diseases 0.000 description 21
- 230000000052 comparative effect Effects 0.000 description 20
- 238000012360 testing method Methods 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 241000283973 Oryctolagus cuniculus Species 0.000 description 11
- 239000000839 emulsion Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 210000003651 basophil Anatomy 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 230000035945 sensitivity Effects 0.000 description 7
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 230000035876 healing Effects 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 229950003937 tolonium Drugs 0.000 description 6
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 6
- 208000024780 Urticaria Diseases 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 206010015150 Erythema Diseases 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Natural products OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 4
- 239000000017 hydrogel Substances 0.000 description 4
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 4
- 230000037307 sensitive skin Effects 0.000 description 4
- 238000010998 test method Methods 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 208000003251 Pruritus Diseases 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000005336 cracking Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 125000003647 acryloyl group Chemical group O=C([*])C([H])=C([H])[H] 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- 231100000021 irritant Toxicity 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 235000008777 kaempferol Nutrition 0.000 description 2
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000008257 shaving cream Substances 0.000 description 2
- 229940104256 sodium taurate Drugs 0.000 description 2
- GWLWWNLFFNJPDP-UHFFFAOYSA-M sodium;2-aminoethanesulfonate Chemical compound [Na+].NCCS([O-])(=O)=O GWLWWNLFFNJPDP-UHFFFAOYSA-M 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000037314 wound repair Effects 0.000 description 2
- NKEQOUMMGPBKMM-UHFFFAOYSA-N 2-hydroxy-2-[2-(2-hydroxy-3-octadecanoyloxypropoxy)-2-oxoethyl]butanedioic acid Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CC(O)(C(O)=O)CC(O)=O NKEQOUMMGPBKMM-UHFFFAOYSA-N 0.000 description 1
- AAJVDDFSOMFLSO-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate;sodium Chemical compound [Na].OCCOC(=O)C=C AAJVDDFSOMFLSO-UHFFFAOYSA-N 0.000 description 1
- 208000025940 Back injury Diseases 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000035484 Cellulite Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000012266 Needlestick injury Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 206010049752 Peau d'orange Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 244000046101 Sophora japonica Species 0.000 description 1
- 235000010586 Sophora japonica Nutrition 0.000 description 1
- HFJHNGKIVAKCIW-UHFFFAOYSA-N Stearyl monoglyceridyl citrate Chemical compound OCC(O)CO.OC(=O)CC(O)(CC(O)=O)CC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O HFJHNGKIVAKCIW-UHFFFAOYSA-N 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229940049638 carbomer homopolymer type c Drugs 0.000 description 1
- 229940043234 carbomer-940 Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 230000036232 cellulite Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 210000003677 hemocyte Anatomy 0.000 description 1
- 229940000351 hemocyte Drugs 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 238000013532 laser treatment Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 229960002969 oleic acid Drugs 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940104261 taurate Drugs 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention particularly discloses a skin repair composition and a preparation method thereof. A skin repairing composition comprises (by weight) quercetin 1-3%, ceramide 5-15%, cholesterol 4-10%, fatty acid 2-4%, and organic amine 0.05-1%; the preparation method comprises the following steps: preparation of phase A: mixing quercetin, ceramide, cholesterol, fatty acid, organic amine, grease, emulsifier and thickener, and stirring; preparing a phase B: mixing water, regulator and sodium carboxymethyl cellulose, and stirring; blending: and (3) blending the phase A and the phase B in a vacuum environment, and homogenizing and stirring to obtain the product. The composition has the advantages of promoting skin wound healing, promoting skin repair and reducing skin allergy.
Description
Technical Field
The application relates to the field of skin repair, in particular to a skin repair composition and a preparation method thereof
Background
After some medical operations (such as laser treatment, tartaric acid skin changing, burn treatment, etc.), the skin of a patient is in a very sensitive and fragile state because of minimal trauma, and if the skin is not cared properly, external stimulation can also cause the skin to release inflammatory factors, so that the skin is red, swollen, itchy, and the like. And most of medical cosmetic operations leave wounds, and the wounds can be repaired within a certain time.
The existing nursing mode generally adopts a skin care product for moisturizing to be smeared on the surface of sensitive skin or ice compress to contract subcutaneous blood vessels, reduce blood flow, reduce vascular permeability and reduce exudation and edema of tissue fluid.
However, such treatment methods can only relieve the sensitive state of the skin, but cannot improve the sensitive state of the skin and promote skin repair.
Therefore, there is a need for an inventive composition that promotes repair of sensitive skin.
Disclosure of Invention
In order to protect wounds, accelerate wound healing and improve skin sensitivity, the application provides a skin repair composition and a preparation method thereof.
In a first aspect, the present application provides a skin repair composition, which adopts the following technical scheme:
a skin repairing composition comprises (by weight) quercetin 1-3%, ceramide 5-15%, cholesterol 4-10%, fatty acid 2-4%, and organic amine or organic ammonium salt 0.05-1%.
By adopting the technical scheme, the dosage ratios of the five components are respectively adjusted by selecting quercetin, cholesterol, ceramide, cholesterol, organic amine or organic ammonium salt. Therefore, the prepared composition can be used for promoting skin repair, accelerating skin wound healing and reducing scar generation. The skin rejuvenating composition also reduces skin sensitivity and skin redness, itching, molting caused by external irritants such as ultraviolet light, irritant solvents, and needle stick abrasion.
In several embodiments of the present application, quercetin may be used in an amount of 1wt%, 2wt%, 3wt%;
preferably, the weight percentage of quercetin is 2wt%.
In several embodiments herein, cholesterol may be used in an amount of 4wt%, 5wt%, 6wt%, 8wt%, 10wt%;
preferably, cholesterol may be used in an amount of 5wt%.
In several embodiments herein, the amount of ceramide may be 5wt%, 8wt%, 10wt%, 12wt%, 15wt%; preferably, the amount of ceramide may be 10wt%.
When the dosage of the quercetin is controlled to be 1-3wt%, the occurrence of inflammatory infection of wounds can be obviously reduced, when the dosage of the quercetin is less than 1wt%, the efficacy of the quercetin is not obvious, and when the dosage of the quercetin is excessive, such as more than 3%, the skin is easy to be sensitive.
When the quercetin and the ceramide are compounded for use, the skin repair can be promoted, the sensitive skin is improved, and the effects of promoting the skin wound healing and relieving the wound sensitivity of the composition can be further improved by adding cholesterol, fatty acid, organic amine or organic ammonium salt.
Preferably, the weight ratio of the quercetin to the ceramide is 2 (5-15).
More preferably, when quercetin is used in an amount of 2wt%, the amount of ceramide may be selected to be 5-15%.
In one embodiment of the present application, the quercetin is present in an amount of 2% by weight and the ceramide is present in an amount of 10% by weight.
Preferably, when the weight percentage of quercetin is 2%, the weight percentage of cholesterol is 4-10%.
In one embodiment of the present application, quercetin is present in an amount of 2wt% and cholesterol is present in an amount of 5wt%.
Preferably, the weight ratio of the ceramide, the cholesterol and the fatty acid is 10 (4-6) to (2-4).
More preferably, the weight ratio of ceramide, cholesterol and fatty acid is 10.
In one embodiment of the present application, the ceramide is present in the composition at 10% by weight, the cholesterol at 5% by weight, and the fatty acid at 3% by weight.
Preferably, the organic amine or organic ammonium salt has 8 or more carbon atoms.
Preferably, the organic ammonium salt is a quaternary ammonium salt having 10 or more carbon atoms.
Still more preferably, the organic ammonium salt is selected from: c8-C22Alkyl trimethyl ammonium chloride, C8-C22At least one of alkyl trimethyl ammonium bromide or polyquaternium.
More preferably, the organic ammonium salt is at least one of cetyltrimethylammonium chloride and octadecyltrimethylammonium chloride.
Preferably, the fatty acid is a free fatty acid having 12 to 28 carbon atoms.
Preferably, the skin repair composition further comprises 2-5% of an emulsifier, 0.1-0.3% of a thickener, 4-6.5% of a regulator, 0.1-1% of sodium carboxymethylcellulose and 5-10% of oil and fat in percentage by weight.
In one or more embodiments of the present application, the skin rejuvenation composition includes, by weight, 1-3% quercetin, 5-15% ceramide, 4-10% cholesterol, 2-4% fatty acid, 0.05-1% organic amine or organic ammonium salt, 2-5% emulsifier, 0.1-0.3% thickener, 4-6.5% regulator, 0.1-1% sodium carboxymethylcellulose, and 5-10% oil and fat.
By adopting the technical scheme, the emulsifier, the thickener, the regulator, the sodium carboxymethyl cellulose, the grease and the like are added into the composition, so that the shape of the composition can be improved, the composition is uniform and smooth in texture, high in stability and easy to store. After the regulator, the sodium carboxymethyl cellulose and the grease are added, the water loss of the composition is reduced, so that the composition can keep skin moist after being coated on the surface of the skin, the water loss of the skin is reduced, and the skin repair is promoted. The addition of the sodium carboxymethyl cellulose can improve the dynamic regulation of the composition on moisture, on one hand, the viscosity of the composition in the form of emulsion is improved, so that the adhesive force of the composition on the skin surface is improved, on the other hand, the composition and the regulator are matched with each other, so that the effect of free water in the composition can be dynamically regulated, and therefore, when a skin wound oozes tissue fluid, the skin wound can be absorbed in time, the wound environment is kept moist, and an environment is provided for wound repair. On the other hand, sodium carboxymethyl cellulose and a conditioning agent can release bound water when the surface of the composition loses water due to exposure, thereby reducing cracking of the composition due to surface drying.
Preferably, the skin repair composition consists of the following components in percentage by weight: 1-3% of quercetin, 5-15% of ceramide, 4-10% of cholesterol, 2-4% of fatty acid, 0.05-1% of organic amine or organic ammonium salt, 2-5% of emulsifier, 0.1-0.3% of thickener, 4-6.5% of regulator, 0.1-1% of sodium carboxymethylcellulose, 5-10% of grease and the balance of water.
More preferably, the skin repair composition comprises, by weight, 2% of quercetin, 10% of ceramide, 5% of cholesterol, 3% of fatty acid, 0.5% of organic amine or organic ammonium salt, 3% of emulsifier, 0.2% of thickener, 5.5% of regulator, 0.6% of sodium carboxymethylcellulose, 8% of grease and the balance of water.
Preferably, the emulsifier is at least one of polyglycerol-3 distearate, glycerol stearate and citric acid ester.
More preferably, the emulsifier is selected from polyglyceryl-3 distearate.
By adopting the technical scheme, at least one of polyglycerol-3 distearate, glycerol stearate and citric acid ester is selected as an emulsifier, so that an oil phase in the raw materials, such as quercetin, cholesterol and a ceramide water phase, such as water, and sodium carboxymethylcellulose are uniformly mixed to prepare an emulsion; and the prepared emulsion has uniform texture, can be stored for a long time and is not easy to separate.
Preferably, the thickener is a copolymer of hydroxyethyl acrylate and sodium acryloyldimethyl taurate.
Preferably, the regulator comprises xanthan gum, carbomer; wherein the weight ratio of the xanthan gum to the carbomer is 1.
More preferably, the weight ratio of xanthan gum to carbomer is 1
By adopting the technical scheme, the combination of the xanthan gum and the carbomer can improve the dispersibility and viscosity of each component in the composition, so that the layering of the composition is reduced, the carbomer has certain anti-inflammatory and antiviral effects, and the antibacterial capability after the combination is added is further improved, so that the skin inflammation condition is reduced.
After the xanthan gum and the carbomer are compounded in proportion, the composition also has the following effects
When the weight ratio of the xanthan gum to the carbomer is more than 1 and is 40-60, the obtained composition can remarkably accelerate the healing speed of the early wound healing period; and when the weight ratio of the xanthan gum to the carbomer is less than 1, the collagen can be used for promoting the healing of the later period of the wound, wherein the weight ratio of the xanthan gum to the carbomer is 40-60. By combining the two conditions, when the weight ratio of the xanthan gum to the carbomer is 1-60, the speed of the whole process of wound healing is accelerated more favorably.
In one embodiment of the present application, the weight ratio of xanthan gum, carbomer and sodium carboxymethylcellulose is 1.
More preferably, the weight ratio of the xanthan gum, the carbomer and the sodium carboxymethyl cellulose is 1.
The xanthan gum, the carbomer and the sodium carboxymethylcellulose are mixed according to a certain proportion and then added into the composition to form hydrogel, and the hydrogel can dynamically regulate free water in the composition. When the composition is applied to the surface of a wound and the wound exudes a large amount of tissue fluid in the early healing period, the hydrogel absorbs excessive tissue fluid, so that the effect of influencing the adhesion stability of the composition on the skin surface due to the excessive amount of the extravasated tissue fluid is reduced, and when the composition is applied for a long time and the outer side of the composition is dehydrated and dried, the hydrogel replenishes water to the exposed surface of the composition, so that the moisture and flexibility of the composition are maintained, and the cracking of the composition is reduced.
Preferably, the oil or fat is any one selected from caprylic triglyceride, capric triglyceride and squalane.
More preferably, the oil or fat is caprylic triglyceride.
Preferably, the thickener is a copolymer of hydroxyethyl acrylate and sodium acryloyldimethyl taurate.
In a second aspect, the present application provides a method for preparing a skin repair composition, which adopts the following technical scheme:
a method of preparing a skin rejuvenation composition comprising the steps of:
preparation of phase A: mixing quercetin, ceramide, cholesterol, fatty acid, organic amine salt, emulsifier, thickener and oil according to formula ratio, stirring and heating to 80-85 deg.C, and stirring at constant temperature for 15-20min;
preparation of phase B: blending the water, the regulator and the sodium carboxymethylcellulose according to the formula ratio, stirring and heating to 85-90 ℃, and stirring for 15-20min;
blending: mixing the A phase and the B phase under vacuum, homogenizing at 75-85 deg.C for 5-8min at a homogenizing speed of 45-50 times/min, and stirring to obtain the final product.
Preferably, the vacuum degree of the vacuum environment in the blending step is-0.03 MPa.
By adopting the technical scheme, the A phase and the B phase are respectively and uniformly mixed and then are blended and homogenized, so that the dispersibility of each effective component in the prepared emulsion is better, the stability of each component in the emulsion is better, and the prepared emulsion is not easy to layer.
In summary, the present application has the following beneficial effects:
1. by selecting quercetin, ceramide, cholesterol, fatty acid, organic amine or organic ammonium salt and limiting the dosage of the 5 raw materials, the prepared composition can promote wound healing, reduce skin sensitivity, protect skin and promote skin repair after being smeared on the surface of the skin.
2. By adding the regulator into the composition and limiting the dosage ratio of the xanthan gum to the carbomer in the regulator, the repair speed of the composition to wounds in different periods is improved, and the adhesiveness of the composition on the skin surface and the storage stability of the composition can be improved.
3. According to the preparation method, the phase A and the phase B are respectively and uniformly mixed, and then the phase A and the phase B are blended and homogenized, so that the dispersibility of each effective component in the prepared emulsion is better, the stability of each component in the emulsion is better, and the prepared emulsion is not easy to layer.
Detailed Description
The starting materials for this embodiment are all commercially available.
Quercetin, a 98% extract of Sophora japonica, quercetin, produced by biosciences, inc., of Simian Ashland.
Cholesterol, purchased from Merck, product number c8667.
The fatty acid, selected as Oleic acid (CAS number 112-80-1), was purchased from Ji Shanghai to Biochemical technology, inc.
Ceramide, commercially available from Jiangsu, xinjiang Biotechnology, inc.
An organic amine salt, selected as cetyltrimethylammonium chloride, was purchased from Merck.
The thickener is a copolymer of hydroxyethyl acrylate and sodium acryloyldimethyl taurate, which is a copolymer of hydroxyethyl acrylate sodium acryloyldimethyl taurate purchased from Gandong Gaoyang science and technology Limited.
And the grease is selected from caprylic triglyceride.
Polyglycerol-3 distearate was purchased from gayoto gaiche technologies ltd.
Glycerol stearate citrate was purchased from Simeiquan Biotech, inc. of Shenzhen.
The thickener was a copolymer of hydroxyethyl acrylate and sodium acryloyldimethyl taurate, purchased from sebick EMT10, france.
Xanthan gum was purchased from jungbunzlauer, switzerland.
Carbomer was purchased from carbomer 940, manufactured by shanghai aerial biotechnology, inc.
Sodium carboxymethylcellulose was purchased from food grade CMC (sodium carboxymethylcellulose) model FH9 manufactured by doupino food ingredients ltd, zhejiang.
A skin rejuvenation composition prepared by:
preparation of phase A: the preparation method comprises the following steps of blending quercetin, ceramide, cholesterol, oleic acid, hexadecyl trimethyl ammonium chloride, polyglycerol-3 distearate (or glyceryl stearate citrate serving as an emulsifier), hydroxyethyl acrylate/sodium acryloyldimethyl taurate copolymer (serving as a thickening agent) and caprylic acid/capric acid triglyceride (serving as grease) according to formula ratio, stirring and heating to 82 ℃, then stirring at constant temperature for 18min, and stirring at the speed of 25 times/min.
Preparation of phase B: mixing water, regulator (xanthan gum and/or carbomer), and sodium carboxymethylcellulose, stirring, heating to 88 deg.C, and stirring for 18min at 25 times/min.
Blending: mixing the A phase and the B phase under the vacuum degree of-0.03 MPa, homogenizing at 80 deg.C at a homogenizing speed of 50 times/min for 6min, stirring at 25 times/min for 12min. And cooling to 45 ℃ to obtain the product.
Examples
The raw material formulation of examples 1-12 is shown in Table 1, and examples 1-12 were prepared using the above-described preparation method.
TABLE 1, examples 1-12 raw material ratios (g)
Note: the emulsifier is polyglycerol-3 distearate;
the thickening agent is a copolymer of hydroxyethyl acrylate and acryloyl dimethyl sodium taurate;
the oil is caprylic triglyceride;
the balance is the total weight of the system adjusted to 100g by water.
Comparative example
The raw material formulation of comparative examples 1 to 7 is shown in Table 2, and the production methods of comparative examples 1 to 7 are the same as those of the examples.
TABLE 2
Note: the emulsifier is polyglycerol-3 distearate;
the thickening agent is a copolymer of hydroxyethyl acrylate and acryloyl dimethyl sodium taurate;
the oil is caprylic triglyceride;
the balance is water for adjusting the total weight of the system to 100g;
means that the starting material is not added;
comparative example 4 was prepared by replacing quercetin with equal weight of kaempferol;
comparative example 7 is the replacement of cetyltrimethylammonium chloride with an equal weight of ethanolamine.
Performance test
1. Detection of wound healing promoting performance of skin repair composition
1.1 test animals: 8 week old rats, weighing 200 + -20 g, were randomly divided into 19 groups of 4 rats each, and the rats were housed in a single cage during the test period.
1.2 test methods
1.2.1 rat wound model construction: the back of the rat was shaved and skin prepared one day before molding using an animal shaver and animal shaving cream. On the day of modeling, the rats were anesthetized by intraperitoneal injection using 3% sodium pentobarbital at a dose of 45mg/kg of the body weight of the rats. The rat dorsal skin preparation area was disinfected with 75% medical alcohol. Then, holes are symmetrically formed on two sides of the back of the rat respectively, the diameter of each hole is 10mm, then the circular hole endothelium lower fascia layer is subtracted from the operation scissors and the operation forceps along the hole forming mark, the skin in the hole is peeled off, and sterile gauze is used for compression hemostasis.
1.2.2 rat wound administration: the day of molding was recorded as the test day 1, and the skin-repairing composition obtained in example or comparative example was applied to a wound on one side of the rat and recorded as the application side; the other side is marked as blank side without processing. Experimental days 3, 5, 7, 9, 11, 13 rats were dressing changes with skin repair compositions: the original composition was wiped off with tweezers and a cotton swab, the surface cleaned, and the skin repair composition reapplied.
1.3 test record: wound image acquisition and wound healing degree calculation
When changing dressings on the 5 th, 9 th and 13 th days of the experiment, the crust skin on the surface of the wound is uncovered, the wound is photographed, and the graduated scale is placed in the photographing picture. The wound area was calculated according to the scale readings taken in the picture.
The degree of wound healing is calculated according to the following formula:
degree of wound healing (%) = (S)1-Sn)/S1×100％；
Wherein S is1For the wound area in the first day of the experiment, SnThe area of the wound on the nth day of the experiment.
The results of the measurements are shown in Table 3
TABLE 3 test of the wound healing promoting Performance of the compositions of examples 1-12 and comparative examples 1-7
Note: mean wound healing the mean of the wound healing of four rats in the group was taken.
As can be seen from table 3, in combination with examples 1 to 3 and comparative examples 1 to 7, the skin wound healing can be effectively accelerated by adding quercetin, ceramide, cholesterol, fatty acid, and organic ammonium salt, and combining these 5 components, and particularly, when the amount of quercetin is 2%, the amount of ceramide is 10%, the amount of cholesterol is 5%, the amount of fatty acid is 3%, and the amount of organic ammonium salt is 0.5%, the skin healing composition has a particularly significant effect in promoting wound healing. In combination with comparative examples 1-5, it can be seen that the extent of wound healing is significantly reduced in the absence of any of the 5 components. When quercetin is replaced with kaempferol of equal weight, the composition has reduced wound repair promoting effect.
When the ratio of the dosage of the quercetin to the dosage of the cholesterol is 2-15, the composition has a remarkable effect on promoting wound healing, particularly when the dosage of the quercetin is 2%, the composition has a remarkable effect on promoting wound healing, and further when the dosage of the quercetin is 2%, the dosage of the cholesterol is 10%, the composition has a remarkable effect on promoting wound healing.
In combination with examples 2, 10, 11 and 12, it can be seen that the wound healing effect of the composition can be further optimized by adjusting the ratio of xanthan gum to carbomer in the composition, the healing speed of the wound healing in 0-5 days can be accelerated when the dosage ratio of xanthan gum to carbomer is increased, and the healing speed of the wound healing in 5-9 days and 9-13 days can be accelerated when the dosage ratio of xanthan gum to carbomer is decreased. By combining the two conditions, when the dosage ratio of the xanthan gum to the carbomer is 1; on day 13, the average degree of wound healing in the mouse could reach 92.5%.
In view of the above, the compositions of the present application, when used to promote wound healing, may be applied with a composition having a xanthan gum to carbomer ratio higher than 1.
In combination with example 2, comparative example 2 and comparative example 7, it can be seen that the repair speed of the skin repair composition on the wound can be accelerated by selectively adding the organic ammonium salt, and particularly, when the organic ammonium salt is selected to be quaternary ammonium salt with the carbon number of more than 8, for example, when the organic ammonium salt is selected to be hexadecyl trimethyl ammonium chloride, the effect of the skin repair composition on promoting wound healing can be remarkably improved.
2. anti-UV damage detection
2.1 test animals: 8 weeks old rats 44, 200 + -20 g in weight, were divided into 11 groups of 4 rats each. The backs of the rats were shaved and skin prepared using an animal shaver and animal shaving cream.
2.2 test methods: coating a skin repairing composition by taking rat vertebra as a central axis and one side as a treatment area; the other side is blank and is not processed. 11 groups of rats, to which the skin-repairing compositions obtained in examples 1 to 5 and comparative examples 1 to 7 were applied, respectively, were treated dailyIrradiating for 18 hours at 0.3J/cm2The skin condition of the back of the rat was observed on the sixth day after 5 consecutive days to check whether skin problems such as erythema, molting, and chapping occurred.
2.3 Experimental results are shown in Table 2
TABLE 4 Back injury in rats irradiated with UV light
In combination with the examples 1-5 and the comparative examples 1-7, the quercetin, ceramide, cholesterol, fatty acid, and organic ammonium salt can be used for reducing the damage of the skin caused by ultraviolet rays after being combined and proportioned, after the skin is irradiated by ultraviolet rays for 18 hours every day for 5 consecutive days, the back skin of the rat coated with the examples 1-5 has no other obvious change except for the darkening of the color, while the rats of the comparative examples 1-7 have different degrees of erythema, moulting cracking and the like. It is demonstrated that the skin rejuvenation composition prepared in this application has the effect of reducing the exposure of the skin to uv light.
3. Basophil degranulation inhibition capability test
3.1 Experimental animals
20 normal rabbits were treated by skin preparation on the backs of the rabbits.
3.2 construction of Rabbit allergy model
On the 0 th day of the experiment, 1ml of a 50wt% ovalbumin aqueous solution was injected subcutaneously into the back of the rabbit, and the injection was performed once more on the 2 nd and 4 th days of the experiment.
3.3 test methods
Preparation of the reagent:
EDTA Na solution: EDTA Na is dissolved in physiological saline, and the weight percentage of the EDTA Na in the EDTA Na solution is 0.1%.
Toluidine blue solution, toluidine blue was dissolved in 5% by weight of aluminum sulfate solution, and the toluidine blue was 0.8% by weight in the toluidine blue solution.
Before injection on the 0 th day of the experiment, the rabbit was punctured subcutaneously to take 2ml of blood, heparin was anticoagulated, serum was centrifugally separated (2000 r/min,30 min), 10. Mu.L of serum was taken and placed in a 37 ℃ incubator for 5min, then 40. Mu.L of EDTA Na solution and 50. Mu.L of toluidine blue solution were added dropwise, after shaking, the rabbit was placed in a 37 ℃ incubator for 40min, and then the rabbit was taken out for aspiration of cell sap, and a hemocyte counting plate was added dropwise, and the number of basophilic cells in 9 large cells was counted by low power microscope (10X 8) and recorded as a control group.
From the 3 rd day of the experiment, 19 rabbits were applied with the skin-repairing compositions obtained in examples 1 to 12 and comparative examples 1 to 7, respectively, and the composition applied on the previous day was wiped off every day, and the application was resumed, while another rabbit was a blank control without the application of the composition.
On the 18 th day of the experiment, 2ml of blood is obtained by subcutaneous puncture on the back of the rabbit, heparin is used for anticoagulation, serum is centrifugally separated (2000 r/min,30 min),
and (3) taking 10 mu L of serum, placing the serum in a 37 ℃ thermostat for standing for 5min, then dropwise adding 40 mu L of EDTA Na solution and 50 mu L of toluidine blue solution, placing the serum in the 37 ℃ thermostat for standing for 40min after oscillation, sucking cell sap, dropwise adding a blood counting plate, detecting by using a low-power microscope (10 multiplied by 8), counting the number of basophilic cells in 9 big grids, and marking as an experimental group.
3.4 evaluation of test results
Basophil degranulation re-fraction (%) = (number of basophils in control group-number of basophils in experimental group)/number of basophils in control group
The practical results are shown in the table
TABLE 5 Degranulation and Re-fraction of basophils in example 1 and comparative examples 1 to 4
Combining examples 1-12 with comparative examples 1-7, it can be seen that the basophil degranulation fraction after the skin repair composition is applied to the back of the allergic rabbit is significantly lower than that of comparative examples 1-7 and the blank example, which shows that the compositions prepared in examples 1-12 of the present application can reduce the skin sensitivity and reduce the occurrence of skin allergy. In examples 2, 10, 11 and 12 in which the ratio of xanthan gum to carbomer was adjusted, the basophil degranulation fraction of example 2 was 17.8%, indicating that the composition had the best effect of reducing skin irritation when the adjusting agent was a mixture of xanthan gum and carbomer, and the weight ratio of xanthan gum to carbomer was 1.
4. The anti-sensitivity capability detection test method comprises the following steps: 30 healthy volunteers without allergy history are recruited, the back skin of the volunteers is disinfected and divided into 8 experimental areas, and the area of each experimental area is 9cm2The skin repair compositions of example 2 and comparative examples 1-7 were applied to the cellulite-producing surface of 7 test areas of volunteers' backs after 5 minutes by puncturing the skin with a sterile intradermal needle and withdrawing the skin from the test areas, respectively, and the other test area was used as a blank control without any treatment.
And measuring the area of the wheal when the needle is punched for 5min, 10min and 30min, and calculating the reduction rate of the area of the wheal for 10min and 30 min.
Windage area reduction rate (%) = (S)0-Sn)/S0
Wherein,
S0the area of the wheal when the needle is pricked for 5 min;
Snthe area of the wheal when the needle is punctured for 10min or 30 min.
The test results are shown in Table 6
TABLE 6 Histamine test by acupuncture
It can be seen from example 2, comparative examples 1-7, and table 6 that the composition prepared by the present application can reduce skin sensitivity and accelerate the dissipation of wheal by selecting and blending quercetin, ceramide, cholesterol, fatty acid, and organic ammonium salt in a certain ratio.
The composition prepared by the application can be applied to sensitive skin after medical and art, reduces the probability of skin allergy, promotes volatilization of wounds in medical and art, and reduces symptoms such as skin redness and swelling and pruritus caused by postoperative skin sensitivity.
The specific embodiments are only for explaining the present application and are not limiting to the present application, and those skilled in the art can make modifications to the embodiments without inventive contribution as required after reading the present specification, but all the embodiments are protected by patent law within the scope of the claims of the present application.
Claims (10)
1. The skin repair composition is characterized by comprising 1-3wt% of quercetin, 5-15 wt% of ceramide, 5wt% of cholesterol, 3wt% of fatty acid, 0.5 wt% of organic amine or organic ammonium salt, 3wt% of emulsifier, 0.2 wt% of thickener, 5.5 wt% of regulator, 0.6 wt% of sodium carboxymethylcellulose, 8wt% of grease and the balance of water; the regulator is a composition of xanthan gum and carbomer; wherein the weight ratio of the xanthan gum to the carbomer is 1.
2. The skin rejuvenation composition as defined in claim 1 wherein said organic amine or ammonium salt has 8 or more carbon atoms.
3. The skin rejuvenation composition as defined in claim 2 wherein said organic ammonium salt is a quaternary ammonium salt having 10 or more carbon atoms.
4. A skin rejuvenation composition according to claim 3 wherein said organic ammonium salt is selected from the group consisting of: c8-C22Alkyl trimethyl ammonium chloride, C8-C22At least one of alkyl trimethyl ammonium bromide or polyquaternium.
5. The skin rejuvenation composition as defined in claim 4 wherein said organic ammonium salt is at least one of cetyltrimethylammonium chloride and octadecyltrimethylammonium chloride.
6. The skin rejuvenation composition as claimed in claim 1 wherein said fatty acid is a free fatty acid having from 12 to 28 carbon atoms.
7. A skin rejuvenation composition as claimed in claim 1 wherein: the emulsifier is at least one of polyglycerol-3 distearate, glycerol stearate and citrate.
8. A skin rejuvenation composition as claimed in claim 1 wherein: the thickening agent is a copolymer of hydroxyethyl acrylate and sodium acryloyl dimethyl taurate.
9. A skin rejuvenation composition as claimed in claim 1 wherein: the oil is selected from caprylic triglyceride, capric triglyceride and squalane.
10. A method of preparing a skin rejuvenating composition as defined in any one of claims 1 to 9 which comprises: the method comprises the following steps:
preparation of phase A: blending quercetin, ceramide, cholesterol, fatty acid, organic amine salt, emulsifier, thickener and oil according to formula ratio, stirring and heating to 80-85 deg.C, and stirring at constant temperature for 15-20min;
preparation of phase B: mixing the water, the regulator and the sodium carboxymethylcellulose according to the formula ratio, stirring and heating to 85-90 ℃, and stirring for 15-20min;
blending: mixing the A phase and the B phase under vacuum, homogenizing at 75-85 deg.C for 5-8min at a homogenizing speed of 45-50 times/min, and stirring to obtain the final product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111617732.1A CN114288305B (en) | 2021-12-27 | 2021-12-27 | Skin repair composition and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111617732.1A CN114288305B (en) | 2021-12-27 | 2021-12-27 | Skin repair composition and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114288305A CN114288305A (en) | 2022-04-08 |
| CN114288305B true CN114288305B (en) | 2022-11-01 |
Family
ID=80969104
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111617732.1A Active CN114288305B (en) | 2021-12-27 | 2021-12-27 | Skin repair composition and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114288305B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110402134A (en) * | 2017-03-01 | 2019-11-01 | 布茨公司 | Cosmetic skin care composition |
| CN112336649A (en) * | 2020-11-09 | 2021-02-09 | 江南大学 | Preparation method and product of skin co-permeation carrier of ceramide and fat-soluble active substance |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004014615A1 (en) * | 2004-03-23 | 2005-10-13 | Beiersdorf Ag | Taurine-containing preparations for improving the skin barrier |
| ATE468100T1 (en) * | 2006-10-13 | 2010-06-15 | Evonik Goldschmidt Gmbh | SKIN TREATMENT COMPOSITION |
| US10137073B2 (en) * | 2016-01-02 | 2018-11-27 | L'oreal | Cosmetic compositions comprising ceramides and cholesterol |
-
2021
- 2021-12-27 CN CN202111617732.1A patent/CN114288305B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110402134A (en) * | 2017-03-01 | 2019-11-01 | 布茨公司 | Cosmetic skin care composition |
| CN112336649A (en) * | 2020-11-09 | 2021-02-09 | 江南大学 | Preparation method and product of skin co-permeation carrier of ceramide and fat-soluble active substance |
Non-Patent Citations (1)
| Title |
|---|
| 舒敏保湿类护肤品在敏感性皮肤中的应用指南;何黎等;《中国皮肤性病学杂志》;20191115;第33卷(第11期);第1229-1231页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114288305A (en) | 2022-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108136026A (en) | The composition based on vaseline comprising cationic biocides | |
| CN104587518A (en) | Hyaluronic acid dressing and preparation method thereof | |
| WO2014009118A1 (en) | Composition containing ecotine or hydroxyecotine as an active substances for promoting the regeneration of injured body tissue | |
| CN114191597B (en) | Liquid dressing for repairing skin wound surface and preparation method and application thereof | |
| CN114903981A (en) | Wound repair formula containing recombinant type III collagen | |
| CN108578279B (en) | Application of skin care composition | |
| CN114288305B (en) | Skin repair composition and preparation method thereof | |
| CN112107724A (en) | Liquid dressing and preparation method thereof | |
| CN112354005B (en) | Dressing for promoting healing of burn and scald wound surfaces and preparation method thereof | |
| CN116688212B (en) | III type recombinant collagen dressing with repairing and anti-aging effects and preparation method and application thereof | |
| CN111012944A (en) | Liquid dressing based on alginate and hyaluronic acid and preparation method thereof | |
| CN106880765B (en) | Powder for promoting wound healing | |
| Babickaite et al. | Therapeutic activity of chlorhexidine-poloxamer antiseptic gel on wound healing in rats: a preclinical study | |
| CN104225577A (en) | Double-treatment-course composite cell growth factor hydrogels as well as preparation methods and applications | |
| CN114569629A (en) | Composition for removing scar and repairing skin and preparation method thereof | |
| CN114225100A (en) | Porphyridium-based liquid dressing and preparation method thereof | |
| CN108853369B (en) | Preparation method and application of natural plant antibacterial liquid PAMs hydrogel patch | |
| US20140328955A1 (en) | Methods for treating chronic wounds | |
| CN101837068B (en) | Preparation process of zanthoxylum oil spray and application thereof | |
| CN112807238A (en) | Anti-inflammatory and soothing repair gel for skin and preparation method thereof | |
| CN110420199A (en) | It is a kind of for wound healing and the water gel of cosmetics and its preparation method and application | |
| CN111281940B (en) | Scar-removing composition and preparation method and application thereof | |
| Marlinawati et al. | The Effect of Papaya Leaf Extract Gel (Carica papaya) on Interleukin-1β Expression and Collagen Density (Col1A1) in the Back Incision Wound Healing of Wistar Rats (Rattus norvegicus). | |
| CN117045844A (en) | Dressing containing polysaccharide and preparation method and application thereof | |
| CN113975446A (en) | Medical sterile application formula and manufacturing method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |